TY - JOUR
T1 - Clinical monoclonal B lymphocytosis versus rai 0 chronic lymphocytic leukemia
T2 - A comparison of cellular, cytogenetic, molecular, and clinical features
AU - Morabito, Fortunato
AU - Mosca, Laura
AU - Cutrona, Giovanna
AU - Agnelli, Luca
AU - Tuana, Giacomo
AU - Ferracin, Manuela
AU - Zagatti, Barbara
AU - Lionetti, Marta
AU - Fabris, Sonia
AU - Maura, Francesco
AU - Matis, Serena
AU - Gentile, Massimo
AU - Vigna, Ernesto
AU - Colombo, Monica
AU - Massucco, Carlotta
AU - Recchia, Anna Grazia
AU - Bossio, Sabrina
AU - De Stefano, Laura
AU - Ilariucci, Fiorella
AU - Musolino, Caterina
AU - Molica, Stefano
AU - Di Raimondo, Francesco
AU - Cortelezzi, Agostino
AU - Tassone, Pierfrancesco
AU - Negrini, Massimo
AU - Monti, Sara
AU - Rossi, Davide
AU - Gaidano, Gianluca
AU - Ferrarini, Manlio
AU - Neri, Antonino
PY - 2013/11/1
Y1 - 2013/11/1
N2 - Purpose: To investigate the incidence and clinical relevance of classic and new prognostic markers, IGHV gene mutational status, and chromosomal abnormalities in clinical monoclonal B lymphocytosis (cMBL) compared with Rai stage 0 chronic lymphocytic leukemia (Rai0-CLL). Experimental Design: A group of 136 patients with cMBL and a group of 216 Rai0-CLL cases were investigated prospectively. Results: IGHV-mutated cases were significantly more frequent among cMBLs (P = 0.005), whereas the distribution of CD38 and ZAP-70 positive cases, of patients with NOTCH1 and SF3B1 mutations or exhibiting the major CLL cytogenetic abnormalities, was similar in the two groups. Moreover, no significant differences were found either in IGHV/IGHD/IGHJ gene usage or in the overall prevalence of stereotyped IGHV gene sequences. Cells from cMBL and Rai0-CLL exhibited similar gene and microRNA (miRNA) signatures; in addition, when grouped according to the IGHV mutational status, IGHVunmutated cases showed different transcriptional signatures compared with IGHV-mutated patients, irrespective of the cMBL or Rai0-CLL classification. cMBL diagnosis per se was predictive of longer progression-free survival. Conclusions: Our study based on a prospective series of patients indicates that no major differences exist between the circulating cells from cMBL and Rai0-CLL, at least based on a comparison of the markers used in the study. This possibly suggests that the two conditions mainly differ in the initial size of the monoclonal cell population, which may influence the subsequent timing of clonal expansion and clinical manifestations.
AB - Purpose: To investigate the incidence and clinical relevance of classic and new prognostic markers, IGHV gene mutational status, and chromosomal abnormalities in clinical monoclonal B lymphocytosis (cMBL) compared with Rai stage 0 chronic lymphocytic leukemia (Rai0-CLL). Experimental Design: A group of 136 patients with cMBL and a group of 216 Rai0-CLL cases were investigated prospectively. Results: IGHV-mutated cases were significantly more frequent among cMBLs (P = 0.005), whereas the distribution of CD38 and ZAP-70 positive cases, of patients with NOTCH1 and SF3B1 mutations or exhibiting the major CLL cytogenetic abnormalities, was similar in the two groups. Moreover, no significant differences were found either in IGHV/IGHD/IGHJ gene usage or in the overall prevalence of stereotyped IGHV gene sequences. Cells from cMBL and Rai0-CLL exhibited similar gene and microRNA (miRNA) signatures; in addition, when grouped according to the IGHV mutational status, IGHVunmutated cases showed different transcriptional signatures compared with IGHV-mutated patients, irrespective of the cMBL or Rai0-CLL classification. cMBL diagnosis per se was predictive of longer progression-free survival. Conclusions: Our study based on a prospective series of patients indicates that no major differences exist between the circulating cells from cMBL and Rai0-CLL, at least based on a comparison of the markers used in the study. This possibly suggests that the two conditions mainly differ in the initial size of the monoclonal cell population, which may influence the subsequent timing of clonal expansion and clinical manifestations.
UR - http://www.scopus.com/inward/record.url?scp=84887064418&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-0622
DO - 10.1158/1078-0432.CCR-13-0622
M3 - Article
SN - 1078-0432
VL - 19
SP - 5890
EP - 5900
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 21
ER -
